Protara Therapeutics ( (TARA) ) just unveiled an announcement.
On April 26, 2025, Protara Therapeutics announced positive interim results from its Phase 2 ADVANCED-2 trial of TARA-002 in high-risk NMIBC patients. The trial demonstrated a 100% complete response rate at any time in BCG-Unresponsive patients and a 76% rate in BCG-Naïve patients, with favorable safety and tolerability profiles. These results, presented at the 2025 American Urological Association Annual Meeting, suggest TARA-002’s potential to significantly impact clinical practice by providing an effective alternative to radical cystectomy for NMIBC patients.
Spark’s Take on TARA Stock
According to Spark, TipRanks’ AI Analyst, TARA is a Underperform.
Protara Therapeutics’ stock score reflects the significant challenges faced by early-stage biotech companies. The absence of revenue and persistent cash outflows are major concerns, offset slightly by a strong equity position and low debt levels. Technical indicators suggest neutral momentum, while valuation metrics signal the typical struggles of a company focused on R&D without profitability. Overall, while the company may have potential, the current financial and operational metrics indicate high risk.
To see Spark’s full report on TARA stock, click here.
More about Protara Therapeutics
Protara Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing transformative therapies for cancer and rare diseases. Its lead candidate, TARA-002, is an investigational cell-based therapy in development for non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs). The company is also developing IV Choline Chloride for patients on parenteral nutrition.
YTD Price Performance: -22.58%
Average Trading Volume: 300,544
Technical Sentiment Signal: Hold
Current Market Cap: $158.8M
For a thorough assessment of TARA stock, go to TipRanks’ Stock Analysis page.